2025-05-02 22:12:22
Latest Post
PVR INOX opens 4 screen multiplex at KA Mall, Jabalpur, Madhya Pradesh
HPCL and ADNOC Trading Signs their 1st LNG Trading Supply Agreement 
Fire and Explosion at Premier Explosives Ltd's factory situated at Katepally Village
Colab Platforms Ltd fixes May 21, 2025 as record date for 2 For 1 stock split
RateGain Launches Industry''s First AI-Powered ARI Management Engine
Stock Report
Parmax Pharma Ltd Q3 FY2022-23 net profit at Rs. 1.74 crore
Posted On : 2023-02-12 21:20:46( TIMEZONE : IST )
Parmax Pharma Ltd has reported Standalone financial results for the period ended December 31, 2022.
Financial Results (Q3 FY2023) - QoQ Comparison
The company has reported total income of Rs. 5.3619 crores during the period ended December 31, 2022 as compared to Rs. 2.1415 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs. 1.7436 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs. -0.7025 crores for the period ended September 30, 2022.
The company has reported EPS of Rs. 4.66 for the period ended December 31, 2022 as compared to Rs. -1.88 for the period ended September 30, 2022.
| Financials | Q3 FY2023 | Q2 FY2023 | % Change |
| Total Income | ₹5.3619 crs | ₹2.1415 crs |  150.38% |
| Net Profit | ₹1.7436 crs | ₹-0.7025 crs | 348.20% |
| EPS | ₹4.66 | ₹-1.88 | 347.87% |
Financial Results (Q3 FY2023) - YoY Comparison
The company has reported total income of Rs.5.3619 crores during the period ended December 31, 2022 as compared to Rs.2.8914 crores during the period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.1.7436 crores for the period ended December 31, 2022 as against net profit / (loss) of Rs.-0.5180 crores for the period ended December 31, 2021.
The company has reported EPS of Rs.4.66 for the period ended December 31, 2022 as compared to Rs.-1.38 for the period ended December 31, 2021.
| Financials | Q3 FY2023 | Q3 FY2022 | % Change |
| Total Income | ₹5.3619 crs | ₹2.8914 crs | 85.44% |
| Net Profit | ₹1.7436 crs | ₹-0.5180 crs | 436.60% |
| EPS | ₹4.66 | ₹-1.38 | 437.68% |
Financial Results (9 Months Ended FY2023) - YoY Comparison
The company has reported total income of Rs.9.0672 crores during the 9 Months period ended December 31, 2022 as compared to Rs.11.2091 crores during the 9 Months period ended December 31, 2021.
The company has posted net profit / (loss) of Rs.-0.2770 crores for the 9 Months period ended December 31, 2022 as against net profit / (loss) of Rs.0.1874 crores for the 9 Months period ended December 31, 2021.
The company has reported EPS of Rs.-0.74 for the 9 Months period ended December 31, 2022 as compared to Rs.0.50 for the 9 Months period ended December 31, 2021.
| Financials | 9 Months Ended FY2023 | 9 Months Ended FY2022 | % Change |
| Total Income | ₹9.0672 crs | ₹11.2091 crs |  -19.11% |
| Net Profit | ₹-0.2770 crs | ₹0.1874 crs | -247.81% |
| EPS | ₹-0.74 | ₹0.50 | -248.00% |
Shares of Parmax Pharma Ltd was last trading in BSE at Rs. 34.65 as compared to the previous close of Rs. 33.90. The total number of shares traded during the day was 406 in over 13 trades.
The stock hit an intraday high of Rs. 34.95 and intraday low of 32.35. The net turnover during the day was Rs. 13767.00.
